These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 38138551)

  • 21. Emerging Topical and Systemic JAK Inhibitors in Dermatology.
    Solimani F; Meier K; Ghoreschi K
    Front Immunol; 2019; 10():2847. PubMed ID: 31849996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
    Huang MY; Armstrong AW
    Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.
    Qi F; Liu F; Gao L
    Front Immunol; 2021; 12():790125. PubMed ID: 34868078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review.
    Gómez-García F; Gómez-Arias PJ; Hernandez J; Montilla AM; Gay-Mimbrera J; Aguilar-Luque M; Viguera-Guerra I; Velez García-Nieto A; Isla-Tejera B; Ruano J
    BMJ Open; 2019 May; 9(5):e028303. PubMed ID: 31122999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Janus kinase-signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition.
    Raychaudhuri S; Cheema KS; Raychaudhuri SK; Raychaudhuri SP
    Curr Opin Rheumatol; 2021 Jul; 33(4):348-355. PubMed ID: 34014847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topical Janus kinase inhibitors: A review of applications in dermatology.
    Hosking AM; Juhasz M; Mesinkovska NA
    J Am Acad Dermatol; 2018 Sep; 79(3):535-544. PubMed ID: 29673776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Janus kinase inhibitors for alopecia areata: A narrative review.
    Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
    Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging trends in clinical research on Janus kinase inhibitors for atopic dermatitis treatment.
    Shih PY; Li CJ; Yong SB
    Int Immunopharmacol; 2023 Nov; 124(Pt B):111029. PubMed ID: 37820425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Janus kinase inhibitors in dermatology: Part II. A comprehensive review.
    Chapman S; Gold LS; Lim HW
    J Am Acad Dermatol; 2022 Feb; 86(2):414-422. PubMed ID: 34228996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Janus kinase inhibitors in autoimmune bullous diseases.
    Huang D; Zhang Y; Kong L; Lu J; Shi Y
    Front Immunol; 2023; 14():1220887. PubMed ID: 37492565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?
    Favoino E; Prete M; Catacchio G; Ruscitti P; Navarini L; Giacomelli R; Perosa F
    Autoimmun Rev; 2021 Mar; 20(3):102750. PubMed ID: 33482338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Under Development JAK Inhibitors for Dermatologic Diseases.
    Sideris N; Vakirlis E; Tsentemeidou A; Kourouklidou A; Ioannides D; Sotiriou E
    Mediterr J Rheumatol; 2020 Jun; 31(Suppl 1):137-144. PubMed ID: 32676572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utilization of Topical Ruxolitinib in Dermatology: A Review.
    Kashetsky N; Turchin I
    Skin Therapy Lett; 2023 May; 28(3):8-13. PubMed ID: 37339609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
    Hammitzsch A; Lorenz G; Moog P
    Front Immunol; 2020; 11():591176. PubMed ID: 33193430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dermatologic Applications and Safety Considerations of Janus Kinase Inhibitors.
    Svoboda SA; Johnson N; Phillips M
    Skin Therapy Lett; 2020 Sep; 25(4):6-11. PubMed ID: 33017108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of patient experiences regarding JAK inhibitors for atopic dermatitis, psoriasis, alopecia areata, and vitiligo.
    Sharma D; Gart S; Kitrell B; Lonowski S; Arthur M; Wei EX
    Arch Dermatol Res; 2024 Sep; 316(9):630. PubMed ID: 39292291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
    Fragoulis GE; McInnes IB; Siebert S
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i43-i54. PubMed ID: 30806709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Emerging Role of Janus Kinase Inhibitors in the Treatment of Cancer.
    Karati D; Mahadik KR; Trivedi P; Kumar D
    Curr Cancer Drug Targets; 2022; 22(3):221-233. PubMed ID: 35232350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
    Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
    J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tofacitinib in the treatment of refractory eczemas - a case series.
    Duraisamy P; Jagadeesan S; Thomas J
    J Dermatolog Treat; 2022 Sep; 33(6):2873-2875. PubMed ID: 35642323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.